HIV treatments using a single pill improve adherence and are cheaper to maintain.
HIV medications © LIGHTFIELD STUDIOS - stock.adobe.com
Complexity surrounding HIV treatments leads to an overall decline in adherence, according to the results of a study published in the Journal of Managed Care and Specialty Pharmacy last week. This leads researchers to conclude that switching from a multi-pill treatment to a single pill will improve patient outcomes.
To come to this conclusion, a team of researchers led by Amy Colson, M.D., MPH a research director at AccessHealth MA, a health councilor in Boston, used the Optum Research Database to calculate the rate at which 4,251 HIV patients started, stopped or switched antiretrovirals between January 1, 2018, and December 31, 2019.
The antiretroviral regimens measured included:
bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) (single tablet)
dolutegravir + emtricitabine/tenofovir alafenamide (FTC/TAF+DTG) (multi-tablet)
Monthly HIV-related medical costs for each were:
$699 for B/F/TAF
$770 for DTG/ABC/3TC
$3,570 for DTG+FTC/TDF
$817 for DTG+FTC/TAF
“It remains unclear what the reasons are for these differences,” Colson and her team write. “Because one of the drivers of differences in health care cost was pharmacy costs, it is possible that filling multiple medications contributes to higher costs than filling a single tablet regimen.”
HIV is an extremely expensive disease to treat. As of 2021, there are an estimated 1.2 million people in the United States living with HIV. A study from the same year estimated that the average person with HIV can expect to spend a lifetime average of $326,411 to $490,045, or about $31,147 annually, which is eight to nine times higher than costs associated with cardiovascular disease or diabetes. Factors that contribute to this cost are inpatient and outpatient services, opportunistic infection prevention, non-HIV medications, emergency care, associated testing and treatment. The costliness of HIV treatment can reduce treatment adherence, which can lead to higher mortality rates and further spread of HIV.
For HIV patients new to HIV treatment, the US Department of Health and Human Services (DHHS) first recommends a triple drug regimen to get the virus under control. Patients can then later switch to single drug treatment once viral suppression is achieved. Once treatment is started, it usually takes about three to six months for the virus to become undetectable.
“After weighting and additional covariate adjustment for relevant baseline demographic and clinical characteristic differences, HIV-related medical costs were the lowest for treatment-experienced people with HIV receiving B/F/TAF,” Colson and her team continue. “Selecting the appropriate treatment regimen may help treatment-experienced people with HIV maintain lower HIV-related medical costs.”
HIV + Hepatitis Institute Welcomes RFK, Talks Importance of Ending the HIV Epidemic
February 13th 2025The group released a statement today expressing that they are eager to work with Robert F. Kennedy Jr. to eradicate HIV when steps into his role as the Secretary of Health and Human Services.
Read More
Trump Administration Throws U.S. AIDS Support into Turmoil
February 6th 2025PEPFAR, the main U.S.-funded global AIDS program was given a waiver from the foreign aid freeze, but there is still uncertainty and interruptions, partly because many PEPFAR programs are implemented through USAID, which has been largely shutdown by the news administration.
Read More
RFK Jr. and HIV Denial: He Says He Is Neutral, But...
January 29th 2025In 2021 book attacking Anthony Fauci, M.D., Robert F. Kennedy Jr. casts doubt on HIV being the sole cause of AIDS and presents arguments made by "HIV deniers" that believe it is bystander in the immunosuppression that characterizes AIDS.
Read More